Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 9/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SCN1A | P35498 | 6/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 6/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | MLNR | O43193 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4493112 | 0.82 | CHRM3 (0.53) | CHRM3CHRM1CHRM5CHRM4MEN1 | |
| SCHEMBL4501227 | 0.76 | PKM (0.54) | ALDH1A1HTR2ADRD3 | |
| SCHEMBL4492081 | 0.75 | GAA (0.38) | CHRM3CHRM1CHRM5CHRM4KMT2A | |
| SCHEMBL27780541 | 0.72 | CHRM3 (0.54) | CHRM3CHRM1CHRM5CHRM4MEN1 | |
| SCHEMBL4492860 | 0.72 | GAA (0.49) | MEN1KMT2AALDH1A1 | |
| SCHEMBL381901 | 0.71 | ALDH1A1 (0.52) | MEN1KMT2AALDH1A1 | |
| SCHEMBL737365 | 0.70 | ALDH1A1 (0.46) | MEN1KMT2AALDH1A1 | |
| SCHEMBL27928038 | 0.70 | MAPT (0.50) | CHRM3CHRM1CHRM5CHRM4KMT2A | |
| Hydrochloric Acid SCHEMBL28120286 | 0.70 | PKM (0.56) | CHRM3CHRM1CHRM5CHRM4MEN1 | |
| SCHEMBL1126485 | 0.69 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1527046-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004009546-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | CHRM3 997/4885CHRM1 232/4885CHRM5 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.